Companies
Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.
In Brief This Week: Clarity Pharmaceuticals, Regenxbio, Rocket Pharmaceuticals, Eisai, AstraZeneca
News items for the week of May 22, 2023.
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
EMA's CHMP Recommends BMS's Opdivo, Chemo for Neoadjuvant PD-L1-Positive NSCLC
If approved, the drug combination will be the first immunotherapy-based treatment available in the neoadjuvant setting for NSCLC patients in Europe.
Janssen Seeking European Approval for Carvykti as Earlier Refractory Multiple Myeloma Treatment
The firm submitted data from CARTITUDE-4, which showed the CAR T-cell therapy improved patients' progression-free survival compared to standard-of-care regimens.